ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk

January 25, 2013

In Brief: Hammer Appointed To New Three Year Term, Says As Panel Chairman; ACCC Elects Yarbro, Moorhead

March 16, 1984

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003

Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows

March 30, 2012

In Brief: Moffitt Cancer Center Awarded Core Grant; Biotech Industry Honors Jeffords, Bliley

May 29, 1998

HHS Reports Some Gains In Reducing Health Disparities

February 8, 2002